Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Sah Dinah Ph.D.

2. Date of Event Requiring Statement (MM/DD/YYYY) 6/29/2017

3. Issuer Name and Ticker or Trading Symbol

Voyager Therapeutics, Inc. [VYGR]

(Last) (First) (Middle)

C/O VOYAGER THERAPEUTICS, 75 SIDNEY STREET

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director _____ 10% Owner
___ X ___ Officer (give title below) _____ Other (specify below)
Chief Scientific Officer /

(Street)

CAMBRIDGE, MA 02139

(City) (State) (Zip)

5. If Amendment, Date Original Filed (MM/DD/YYYY)

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	138688	D

*Table II - Derivative Securities Beneficially Owned ( e.g.* , puts, calls, warrants, options, convertible securities)**
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Options (Right to Buy)	4/27/2015 ⁽¹⁾	4/27/2025	Common Stock	15141	$7.2700	D
Stock Options (Right to Buy)	8/26/2015 ⁽²⁾	8/26/2025	Common Stock	9634	$8.3300	D
Stock Options (Right to Buy)	8/26/2015 ⁽³⁾	8/26/2025	Common Stock	23312	$8.3300	D
Stock Options (Right to Buy)	2/1/2016 ⁽⁴⁾	2/1/2026	Common Stock	34854	$11.0900	D
Stock Options (Right to Buy)	2/1/2016 ⁽⁵⁾	2/1/2026	Common Stock	5146	$11.0900	D
Stock Options (Right to Buy)	2/8/2017 ⁽⁶⁾	2/8/2027	Common Stock	9599	$11.83	D
Stock Options (Right to Buy)	2/8/2017 ⁽⁷⁾	2/8/2027	Common Stock	55401	$11.83	D

Explanation of Responses:
(1)	This option vests in 48 equal monthly installments, commencing on 04/27/2015, provided that, as of each such vesting date, Ms.Sah continues to provide services to Voyager Therapeutics, Inc. (the "Company").
(2)	This option vests in 48 equal monthly installments, commencing on 08/26/2015, provided that, as of each such vesting date, Ms.Sah continues to provide services to the Company.
(3)	This option vests in 48 equal monthly installments, commencing on 08/26/2015, provided that, as of each such vesting date, Ms.Sah continues to provide services to the Company.
(4)	This option vests in 48 equal monthly installments, commencing on 02/01/2016, provided that, as of each such vesting date, Ms.Sah continues to provide services to the Company.
(5)	This option vests in 48 equal monthly installments, commencing on 02/01/2016, provided that, as of each such vesting date, Ms.Sah continues to provide services to the Company.
(6)	This option vests in 48 equal month installments commencing on 02/08/2017, provided that, as of each such vesting date, Ms. Sah continues to provide services to the Company. Further, the option requires acceptance before it may be exercised.
(7)	This option vests in 48 equal month installments commencing on 02/08/2017, provided that, as of each such vesting date, Ms. Sah continues to provide services to the Company. Further, the option requires acceptance before it may be exercised.

Remarks:
Exhibit 24.1: Limited Power of Attorney

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Sah Dinah Ph.D. C/O VOYAGER THERAPEUTICS 75 SIDNEY STREET CAMBRIDGE, MA 02139			Chief Scientific Officer

Signatures
/s/ Shannyn Gaughan, As Attorney-in-Fact for Dinah Sah		7/3/2017
^** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.